Rituximab monotherapy for patients with recurrent primary CNS lymphoma

March 8, 2011Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of rituximab as a monotherapy in treating recurrent primary central nervous system lymphoma.
Conducted a systematic review of relevant literature on rituximab and recurrent primary CNS lymphoma.
Analyzed data from studies focusing on treatment outcomes and patient demographics.
Considered various treatments alongside high-dose methotrexate for comparison.
Rituximab showed positive outcomes in symptom management for patients with recurrent conditions.
Overall treatment response rates were improved with the addition of high-dose methotrexate.
Survival rates remained comparable to traditional therapies, indicating a potential alternative approach.

Answers are grounded in this paper and cite their sources.

Systematic review examines rituximab's effectiveness in recurrent primary CNS lymphoma, suggesting potential benefits.

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma,

No takes yet. Share an insight, caveat, or question.

Batchelor et al. (2011) studied this question.

View at Publisher

Ask AI

Bookmark

Share